21 CFR Part 212
21 CFR Part 212 defines PET drug manufacturing controls, including material acceptance, batch documentation, laboratory evidence, final release, and narrowly defined exceptions for unfinished testing.

On this page · 8 sections
- 1What is 21 CFR Part 212?
- 2Which drugs and activities does the rule cover?
- 3Material release starts with controlled incoming lots
- 4Master instructions and batch evidence are different records
- 5Laboratory records must support the specifications
- 6The three release provisions in §212.70
- 7Failures, receiving facilities, and returned product
- 8Record retention and a small retrieval exercise
How does 21 CFR 212 apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01What is 21 CFR Part 212?
21 CFR Part 212 is the federal current good manufacturing practice regulation specifically for positron emission tomography (PET) drugs. It establishes minimum requirements for methods, facilities, and controls used in production, quality assurance, holding, and distribution of PET drugs intended for human use. Its purpose is to ensure the required safety, identity, strength, quality, and purity—not to guarantee that any particular batch is acceptable (§212.2).
Understanding its release vocabulary prevents a consequential mistake. Material release permits an input to be used in production. Final release permits a batch to be used in humans. Conditional final release concerns an unfinished required finished-product test because of an analytical-equipment malfunction; it is not the name for every release with sterility testing pending (§212.1).
Material Release
Authorizes use in PET drug production.
- Components, containers and closures
- In-process materials, packaging and labeling
Final Release
Authoritative decision by a responsible person permitting human use of a batch.
- Finished PET drug batch
- Final-release controls in §212.70
Conditional Final Release
Final release before a required finished-product test is completed because of an analytical-equipment malfunction.
- Narrow conditions in §212.70(f)
- Not the sterility exception in §212.70(e)
Section references below identify binding regulatory requirements. Suggested record arrangements and the fictional exercise are practice examples, not additional legal requirements or FDA guidance.
02Which drugs and activities does the rule cover?
Part 212 applies only to the production, quality assurance, holding, and distribution of PET drugs. Section 212.5(a) directs manufacturers of human drugs that do not meet the PET drug definition to the cGMP requirements in Parts 210 and 211. The distinction is therefore the regulated drug and activity, not a general exemption for a particular institutional setting.
For investigational PET drugs produced under an IND in accordance with Part 312, and PET drugs produced with RDRC approval in accordance with Part 361, §212.5(b) provides a specific choice: meet the statutory cGMP requirement by complying with Part 212 or by producing under the incorporated version of USP Chapter 823. The regulation identifies that version as May 1, 2009, pages 365–369, USP 32/NF 27. This is not a reference to whichever chapter edition happens to be current.
This definition explains the supplied Part 212 provisions. It does not interpret the incorporated chapter or resolve separate licensing, electronic-record, or clinical-use questions.
03Material release starts with controlled incoming lots
Section 212.40 requires written procedures and specifications for components, containers, and closures. Each incoming lot must be uniquely identified and tested or examined against specifications, designated as quarantined, accepted, or rejected, and obtained from a reliable supplier. A lot cannot be used if it fails specifications, including an applicable expiration date, or has not received material release.
The component identity-testing provisions are conditional, not a blanket exemption based on possession of a supplier certificate. The following table separates the branches in §212.40(c).
| Situation | Required approach |
|---|---|
| Finished-product testing ensures the correct components were used | Examine the supplier certificate of analysis for each incoming component lot against written specifications. A specific identity test on those components is not required. |
| Finished-product testing does not ensure the correct components were used | Perform component-specific identity testing on each lot of a component yielding an active ingredient and each lot of an inactive ingredient, subject to the stated intravenous-product exception. |
| Other components, such as solvents or reagents, not covered by finished-product testing | Examine the supplier certificate against specifications. If used to prepare an inactive ingredient on site, identity-test the components used to make it before release for use. |
| An inactive ingredient is an approved section 505 product marketed as a finished drug for intravenous administration | A specific identity test on that ingredient is not required. |
| Containers and closures | Examine a representative sample of each lot against specifications and perform at least visual identification of each lot. |
Handling and storage must prevent contamination, mix-ups, and deterioration. Shipment records must include identity and quantity, supplier name and lot number, receipt date, testing results, rejected-material disposition, and expiration date where applicable (§212.40(d)–(e)). In practice, keeping material status and the supporting acceptance evidence together makes the reason for use—or non-use—easier to reconstruct.
04Master instructions and batch evidence are different records
A master production and control record contains the instructions and specifications for producing a PET drug. A batch production and control record is the unique record that references an accepted master and documents one batch’s production, labeling, and quality control (§212.1). The distinction is between what is prescribed and what occurred.
Section 212.50 requires written procedures that control and document key process parameters and justify deviations. It also requires production-area and equipment cleanliness and suitability checks immediately before use, with records of those checks. The table gives selected record requirements, not an exhaustive field list.
| Aspect | Master record: prescribed information | Batch record: batch-specific information |
|---|---|---|
| Production sequence | Complete production and control instructions, sampling and testing procedures, specifications, and precautions | Major production steps from the approved master; production dates and critical-step times |
| Components | Complete component list and accurate component weights or measurements | Component quantities and identification codes; ingredient amounts or measurements |
| Equipment and labeling | Major equipment identification; container, closure, and packaging descriptions; label specimens or copies | Major equipment used, testing results, and labeling |
| Control and accountability | Radiochemical-yield action limits requiring investigation and corrective action | Initials or signatures for performing or checking significant steps; investigation results |
As a practical document-design choice, give the master reference a prominent location and keep observed results separate from instructions. A completed instruction checklist should not obscure the underlying batch measurements or laboratory evidence.
05Laboratory records must support the specifications
Laboratories must follow written testing and result-documentation procedures. Analytical methods must be suitable for their intended use and sufficiently sensitive, specific, accurate, and reproducible. Laboratory equipment must be suitable and capable of valid results, with documented calibration, inspection, checking, and maintenance under written procedures (§212.60).
The laboratory record is more than a pass/fail entry. Section 212.60(g) requires sample identification, methods, calculations, sample measurements, complete test data, test dates and times, instrument graphs, charts and spectra, comparison with acceptance criteria, and the tester’s initials or signature and test date.
Product specifications must address identity, strength, quality, purity, and, where appropriate, sterility and pyrogens. Before implementing a new specification test procedure, its accuracy, sensitivity, specificity, and reproducibility must be established and documented. An established compendial procedure must first be verified and documented as working under actual-use conditions (§212.70(a)–(b)).
Stability is another documented evidence requirement: §212.61 requires a written testing program, with results used to determine appropriate storage conditions and expiration dates and times. A convenient production schedule is not a substitute for that evidence.
06The three release provisions in §212.70
Read paragraphs (c)–(d), (e), and (f) together, but do not treat them as three interchangeable permissions. Paragraphs (c)–(d) establish ordinary final-release controls; paragraph (e) addresses sterility testing; paragraph (f) creates a narrow analytical-equipment-malfunction route.
Ordinary final release: §212.70(c)–(d)
Before final release, an appropriate laboratory determination must establish that each batch—or each sub-batch when production uses sub-batches—conforms to specifications, except for sterility. Unless conditional final release under paragraph (f) applies, the determination must be completed, associated laboratory data and documentation reviewed and shown to meet specifications except sterility, and a designated qualified individual must authorize final release by dated signature. Paragraph (d) is not a generic unfinished-test waiver.
Sterility timing and follow-up: §212.70(e)
Sterility testing need not be completed before final release, but must start within 30 hours after production is completed. The 30-hour requirement may be exceeded because of a weekend or holiday. If the sample is held longer than 30 hours, the producer must demonstrate that the longer period does not adversely affect it and that the results will be equivalent to results from testing started within 30 hours. Tested samples must come from individual batches and must not be pooled.
If the product fails a sterility criterion, immediately notify all facilities that received it of the test results and provide appropriate recommendations. Document the notification. After completing the investigation, notify all those facilities of the investigation findings. An internal investigation record alone does not satisfy these notification requirements.
Conditional final release: §212.70(f)
This route begins with inability to complete a required finished-product test because of an analytical-equipment malfunction. All six conditions in paragraph (f)(1) apply:
- Have data documenting that preceding consecutive batches made using the same methods demonstrate that the conditionally released batch will likely meet established specifications.
- Determine that all other acceptance criteria are met.
- Retain a reserve sample of the conditionally released batch.
- Promptly correct the malfunction, complete the omitted test using the reserve sample after correction, and document reasonable efforts to prevent recurrence.
- Immediately notify the receiving facility if reserve-sample testing produces an out-of-specification result.
- Document all conditional-release actions: justification, follow-up, completed testing, notifications, and corrective actions to prevent recurrence.
Two further restrictions are decisive. Conditional final release is prohibited if the malfunction prevents a radiochemical identity/purity test or determination of specific activity. Another batch of that PET drug product may not be released until the equipment problem has been corrected and the omitted finished-product test completed (§212.70(f)(2)–(3)).
- Identify required evidenceStart with the product specifications and batch or sub-batch laboratory determinations.
- §212.70(a)–(c)
- Separate sterility from other testingApply the sterility timing and follow-up provisions without treating them as permission to omit other tests.
- §212.70(e)
- Assess any malfunction branchIf applicable, check all six conditions, excluded tests, and the restriction on another batch.
- §212.70(f)(1)–(3)
- Document the decision and required follow-upOrdinary final release requires reviewed evidence and a designated qualified individual’s dated signature; follow-up depends on the applicable provision.
- §212.70(d)–(f)
07Failures, receiving facilities, and returned product
A nonconforming batch must be rejected and controlled against mix-ups. Section 212.71 requires investigation procedures, documented investigation results and rejected-product disposition, and action to correct identified problems and prevent recurrence. If reprocessing is appropriate, it must follow procedures in the product’s approved application, and the finished product must meet specifications except sterility before final release.
Returned product is different: a PET drug product returned because of a complaint or for any other reason may not be reprocessed. It must be destroyed in accordance with applicable Federal and State law (§212.100(d)). Do not extend the nonconforming-batch reprocessing provision to returned PET drug products.
Distribution records connect a batch to its receiving facilities. They must include or refer to each receiver’s name, address, and telephone number; product name and quantity; batch, lot, or control number; and shipment date and time (§212.90(b)). Label information must also appear in the batch production record, and labeling and packaging operations must prevent mix-ups (§212.80(c)–(d)).
Complaints require written handling procedures, designated-person review and investigation of possible specification failures, and a complaint record including the response, investigation findings, and follow-up (§212.100(a)–(c)). In practice, cross-referencing these records by batch identifier helps connect a complaint or late result to the relevant recipients without implying that the records are interchangeable.
08Record retention and a small retrieval exercise
Section 212.110 requires records at the production facility or another location reasonably accessible to responsible facility officials and designated FDA inspectors. All records must be legible, protected against deterioration or loss, and readily available for FDA review and copying. Retain all records and documentation referenced in Part 212 for at least one year from final release, including conditional final release—not merely from production.
Fictional exercise: counting retrieved record groups
A fictional training team selects four invented batch dossiers, A through D. For this exercise only, it defines five record groups per dossier: batch production record, laboratory evidence, release documentation, distribution records, and sterility follow-up. These five groups are an internal counting convention, not a regulatory packet structure or a complete Part 212 checklist.
The target is 4 × 5 = 20 groups. The team retrieves 4 for A, 5 for B, 3 for C, and 4 for D: 4 + 5 + 3 + 4 = 16. The retrieval gap is 20 − 16 = 4 groups, also checkable as 1 + 0 + 2 + 1 = 4. The exercise retrieval rate is 16 ÷ 20 × 100 = 80%.
That percentage measures only retrieval against the invented grouping. It does not establish completeness, compliance, product safety, or eligibility for release, and it is not a reporting calculator. A useful next practice step is to identify each missing group and distinguish an indexing problem from a missing underlying record.
For implementation detail beyond this definition, continue to the PET drug cGMP readiness guide. Keep the central distinction intact: accepting materials, documenting production, authorizing human use, and completing required follow-up are related but different responsibilities.
Frequently asked questions
Q.Does 21 CFR Part 212 cover investigational PET drugs?+
Section 212.5(b) provides a cGMP choice for the specified IND and RDRC pathways: comply with Part 212 or produce under the incorporated May 1, 2009 version of USP Chapter 823. It does not provide an unrestricted exemption from cGMP.
Q.Is §212.70(d) the conditional-release provision?+
No. Paragraph (d) establishes final-release procedures, including authorization by a designated qualified individual’s dated signature. Conditional final release is addressed in paragraph (f).
Q.Can final release occur before sterility testing is complete?+
Yes, under §212.70(e), alongside the other applicable release requirements. Testing must start within 30 hours after production, subject to the stated weekend or holiday provision and longer-hold demonstration. Individual-batch sampling and failure notifications also apply.
Q.Can an unfinished endotoxin test simply be deferred?+
Not under the sterility exception. Section 212.70(e) addresses sterility only. Conditional final release under paragraph (f) requires an analytical-equipment malfunction and compliance with all its conditions and restrictions.
Q.How does a master record differ from a batch record?+
The master defines production instructions and specifications. The unique batch record references an accepted master and documents the production, labeling, and quality control of one batch (§212.1).
Q.How long must Part 212 records be kept?+
At least one year from the date of final release, including conditional final release, under §212.110(c). That is the Part 212 minimum, not a conclusion about other potentially applicable retention obligations.
Q.May returned PET drug product be reprocessed?+
No. Section 212.100(d) prohibits reprocessing a PET drug product returned for any reason and requires destruction in accordance with applicable Federal and State law.
Primary sources
- 212.1 — Regulatory definitions
- 212.2 — PET drug cGMP purpose and minimum requirements
- 212.5 — Applicability and investigational or research pathways
- 212.40 — Components, containers, and closures
- 212.50 — Production controls and master and batch records
- 212.60 — Laboratory controls and test records
- 212.61 — Stability testing and expiry
- 212.70 — Finished-product testing and release
- 212.71 — Nonconforming product
- 212.80 — Labeling and packaging
- 212.90 — Distribution controls and records
- 212.100 — Complaints and returned products
- 212.110 — Record availability, quality, and retention
Further reading
Explore this topic
21 CFR 212 sits inside 2 overlapping topic clusters in our glossary. Every neighbour is one click away.
Drug-product cGMP rules, ICH Q-series, and the regulators that enforce them.
PET / SPECT GMP, decay math, NRC controls and conditional release.
Want to see how 21 CFR 212 could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.
